• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI

    Transitioning from Clinical Production to Commercial Manufacturing

    Clinical Trial Technology

    Regenerative Medicine: Overcoming the supply chain challenges

    The Future of the Pharmaceutical Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness

    Amgen Selects Location For R&D Facility

    Arctoris Opens Oxford R&D Facility

    Almac Group, Exostar Collaborate on IRT Experience

    Northwest Biotherapeutics Expands Management Team
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Amgen Selects Location For R&D Facility

    Catalent Launches Clinical Trial Planning Service

    CatSci Expands Capabilities with Lab Expansion

    PCI Pharma Services Invests in Tredegar, UK Site

    Avantor Boosts Biopharmaceutical Innovation in China
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Smart Tags on Pills Set to Improve Supply Chain Security and Patient Adherence

    Schreiner MediPharm, PragmatIC Form Partnership for Smart Pharma Labels

    Stevanato Group Begins Construction on TEC

    CSafe Global Expands Packaging Portfolio

    CSafe Global Opens Service Centers in Switzerland and Sweden
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness

    Amgen Selects Location For R&D Facility

    Arctoris Opens Oxford R&D Facility

    Almac Group, Exostar Collaborate on IRT Experience

    Charles River Provides Access to Cosmic Antibody Library
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pelican BioThermal Achieves ISO Accreditation

    PhRMA Appoints Federal Advocacy SVP

    CureVac Granted Mfg. Authorization for GMP Production Suite

    Metrics Completes Japanese Regulatory Inspection

    Samsung Biologics Achieves ISO27001 Certification
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Ajinomoto Bio-Pharma Services

    Federal Equipment Company

    Vetter Pharma International GmbH

    Jubilant HollisterStier Contract Manufacturing & Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Jubilant HollisterStier Contract Manufacturing & Services

    Flow Sciences, Inc.

    Ajinomoto Bio-Pharma Services

    Baxter BioPharma Solutions

    CCRM
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
      • Top 20 Pharma & BioPharma
      • Top 10 BioPharma Companies
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Agenda
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Analytical Method Transfer Best Practices

    Avoiding the perils of analytical method transfer

    Analytical Method Transfer  Best Practices
    Analytical Method Transfer  Best Practices
    Analytical Method Transfer  Best Practices
    Analytical Method Transfer  Best Practices
    Related CONTENT
    • Kemwell Provides Services for U.S. Trial
    • Frontida BioPharm Launches Expansion Efforts
    • BioPharma Services Completes 3 FDA Inspections
    • Warning Letters & Close-out Letters
    • Senate Passes FDA Reauthorization Act
    Wayland Rushing, Director, Scientific Affairs, EAG Laboratories11.07.17
    Analytical method transfers (AMTs) are typically performed as a precursor to a critical step in the drug-development timeline, such as bringing on a new manufacturing facility, release testing of clinical or commercial material, or initiating stability studies at a quality-control laboratory. AMTs document that a new internal or external testing laboratory is qualified on the previously validated analytical method in order to generate current Good Manufacturing Practices (cGMP)-compliant data.

    Not as straightforward as implied
    The development of AMTs is neither easy nor simple. According to the U.S. Food and Drug Administration’s (FDA) Analytical Procedures and Methods Validation for Drugs and Biologics: Guidance for Industry, “…analytical procedures should be described in sufficient detail to allow a competent analyst to reproduce the necessary conditions and obtain results within the proposed acceptance criteria.”1 Although this statement implies that the process should be relatively straightforward, it does not mean AMTs are as simple as providing the analytical method to the new testing site and assuming it will be able to execute the method successfully. Differences in instrumentation, techniques, procedures and even interpretations of an analytical procedure can lead to preventable AMT failures. To ensure successful AMTs and avoid preventable failures, it is critical to develop a well-defined transfer plan with open lines of communication.

    The transfer process
    In any technology transfer (process) there are two primary parties involved: the “sending unit” (SU) and the “receiving unit” (RU). The SU, also known as the transferring laboratory, is the source or originating laboratory for the of the analytical procedure. The RU, also known as the receiving laboratory, is the internal or external laboratory being qualified on the analytical procedure.

    While the process of analytical transfers between the SU and RU is typically thought of as straightforward, involving only two sites, the actual process over the lifetime of the analytical method can be very complex, as shown in Figure 1. In today’s environment, transfers can occur between multiple internal and/or external facilities, which may or may not involve the originating lab—the lab that developed and validated the method. For example, an analytical procedure may be developed and validated by a pharmaceutical company’s internal research and development (R&D) lab, then transferred internally to the company’s manufacturing site, and then later transferred to an external contract manufacturing organization (CMO) or contract research organization (CRO). This can occur over a period of months or years.

    Communication is key
    It is vital to understand that the AMT process should never be treated as a checkbox routine. Just because a method has been validated does not mean that the method will transfer. Some AMT failures do occur as the result of true method issues. However, the vast majority are preventable and often caused by miscommunication, misinterpretation of the information provided, or failure to share appropriate information on the method. Utilizing a defined process is the first step to ensure successful technology transfer and eliminate inadequate communication or lack of communication. An example of such a process is shown in Figure 2.

    For successful execution of the transfer plan, both the SU and the RU have multiple responsibilities, as defined in Figure 3.

    In preparation for the transfer, a critical first responsibility of the SU is to gather the information to be provided to the RU. This information will be part of the Transfer Package and should contain the following: analytical data; previous method validation reports—how did it perform under validation; what kind of robustness criteria?; previous transfer reports—how well have transfers occurred in the past?; relevant standard operating procedures (SOPs), including techniques that are defined by SOPs and may not be outlined in the analytical methods; general data, including example chromatograms and trends—how has the method performed over time?; quality-control (QC)/stability data—how is it performing on a day-to-day basis); and a list of previously encountered issues and how these were resolved.2

    To guide transfer activities, it is important to establish communication protocols. These will include:
    • Conducting pre-transfer meeting(s) between the SU and RU to work out details and answer questions;
    • Establishing single points of contact for both the SU and RU; and
    • Establishing cadence for updates (i.e., weekly/bi-weekly meetings).
    Key items in site evaluation
    One of the key steps is a RU site evaluation to ensure that the RU has the resources and experience to perform the transfers and to evaluate any potential differences between the sites:
    • Equipment
    - Are there differences between brands/models of instruments?
    - Are instruments maintained similarly between sites?
    • Lab infrastructure/environmental conditions
    - Direct/indirect sunlight
    - Lighting sources/types
    - Temperature and humidity controls
    • Laboratory reagent sources
    - Which vendors/grades are used?
    • Analyst training
    - How are they trained on the analytical technique?
    - Paper training vs hands-on training

    Types of testing
    As defined in USP 1224, there are many acceptable approaches to accomplish an analytical method transfer.3 Several factors should be evaluated when determining which type of transfer is appropriate for the product/situation:
    • Timing
    • Cost
    • Logistics
    • Instrumentation/method changes
    • Compendia
    When performing this evaluation, it is important to note that some of these factors can have negative impacts on the other factors. For example, designing an AMT to perform the transfer in the shortest time frame may not be the most cost-effective manner. It is therefore important to understand key drivers for the transfer and potential impacts of a proposed transfer approach.3

    Comparative testing
    The most common method for AMT is comparative testing. As defined in USP 1224, comparative testing requires the analysis of the same set of samples by both the SU and the RU.4
    Choosing the correct, or appropriate, samples can be critical to ensure a successful transfer. Utilizing multiple lots if available is recommended; relying on a single lot may be risky, especially if there is some lot-to-lot variability observed and/or the process involves a drug product method. For impurity methods, ensure that the samples contain the impurities detailed in the method; if the samples do not, the use of aged/expired samples, spiked samples or forced degraded samples is highly recommended. Clinical trial material that is actively being used and commercial material on the market should not be used in the transfer.

    Co-validation or multisite validation
    With the co-validation or multisite approach, the RU executes some aspects of method validation. This typically involves reproducibility testing in conjunction with the SU. Although this can be an efficient way to transfer the method, it can lead to delays in finalizing the validation report. If, for example, failures are encountered by the RU during its portion of the testing, validation will be delayed until all transfer issues are resolved.

    Revalidation
    Revalidation or partial revalidation is also considered acceptable for AMTs. It is commonly performed when the SU is unable to participate in the transfer activities. This process generally requires more time and is more expensive compared with the other modes of transfer. As part of the process to demonstrate that it is qualified, the RU performs a subset of the original validation. Typical parameters may include:
    • Accuracy
    • Precision
    • Linearity
    • Robustness
    Revalidation may also be required in case of a method change. For example, the SU may use a different brand or model of instrument than the RU. In this case, revalidation may be required to demonstrate that the method is not only transferred, but that it is also validated on the new instrument.5

    Waiver
    In a limited number of cases, AMTs may be omitted. One example would be methodologies in which the presence of the sample does not impact the analytical technique and the RU already has documented experience on that technique (e.g., pH, loss on drying, melting point, etc.). A justification should always be prepared detailing the reasons why this approach is appropriate.

    Training
    Proper training is another prerequisite for AMT success. Generally, three types of training methods are used during AMTs:
    • Remote. This is the simplest and most commonly used training process. The RU trains solely based on the information provided in the transfer package. However, remote training is also the source of most preventable failures.
    • Onsite. In this case, the SU trains the RU onsite (at either the SU or RU lab). This method is generally preferred for biotechnology companies and/or in case of complex AMTs. It is costlier and more time-consuming than remote training, but it generally leads to relatively few transfer issues.
    • Dual onsite. This training process is the most complex and is typically used only for extremely complex methods. It has a very low failure rate, but it is very time consuming.
      -The RU sends its analysts to train at the SU laboratory and to generate data with the SU.
      -The RU analyst and the trainer from the SU then travel to the RU to generate data at the RU.

    Data evaluation and transfer report
    The final steps of a successful transfer are to evaluate the transfer data against the pre-established acceptance criteria and to prepare the transfer report. While it is more common for the SU to write the transfer report, it is perfectly acceptable for the RU to do it. This report should include the results, as well as any discrepancy of these results in relation to acceptable criteria; it also should be reviewed and approved by both the RU and SU.

    Common issues
    To avoid common pitfalls in the AMT process, it is important to recognize them:

    Unclear method instructions
    These are at the root of most common issues. In this case, the RU interprets a method instruction differently than the SU. For example, a method may require the analyst to “prepare a 1-ppm solution,” but PPM can be defined as either gravimetric (µg/g) or volumetric (µg/mL).

    Method not written for external use
    This issue should be caught during the initial evaluation stage, but many times it is not. An analytical method being transferred should not refer to or rely on any internal documentation or SOPs that are not provided to the RU.

    Impurity methods: Relative response factors (RRFs)
    When transferring an impurity/degradant method that relies on RRFs, do not assume that RRFs will be the same between laboratories. Always verify the RRFs at the RU.

    Arbitrary acceptance criteria
    Acceptance criteria must be meaningful and appropriate for the method and should be based on the method’s day-to-day performance. Setting arbitrary criteria can lead to faulty transfers—either in failing a transfer that should have passed from a practical, scientific standpoint based on the method’s historical performance or in passing a transfer that should have failed.

    Bias
    A commonly overlooked issue is bias in the obtained results. Bias refers to a systematic difference or error of results between the RU and SU. For example, the acceptance criteria for an assay method transfer may require that the RU and the SU data agree within ±1% for triplicate analysis of three lots. The RU data fall within this range, but all results of the RU are 0.8% lower than the SU. While this passes the acceptance criteria, it could still mean that there is a systematic difference or error (bias) associated with the RU data that could result in the RU failing release specifications for the material being tested that should have passed.

    Summary
    Analytical method transfers are a regulatory requirement. A successful AMT requires accurate communication between the transferring and receiving laboratories and a clear plan with defined roles and responsibilities. In most cases, simply asking the right questions can prevent AMT failure. But the most important takeaway is to never treat an AMT as a checkbox routine. Take time to perform a risk analysis that considers the previous experience and knowledge of the RU, the complexity and specifications of the product, and the analytical procedure itself. This small investment will inform decisions about the analytical methods to be transferred, the extent of the transfer activities, and the implementation strategy—and significantly improve the rate of AMT success. 

    References
    1. U.S. Department of Health and Human Services, Food and Drug Administration. Analytical Procedures and Methods Validation for Drugs and Biologics: Guidance for Industry. July 2015. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM386366.pdf
    2. Ermer J, Limberger M, Lis K, Wätzig H. The transfer of analytical procedures. J Pharm Biomed Anal. 2013;85:262–276. doi: 10.1016/j.jpba.2013.07.009.
    3. USP 1224: Transfer of Analytical Procedures (general information). Online. Last accessed October 25, 2017. https://hmc.usp.org/sites/default/files/documents/HMC/GCs-Pdfs/c1224.pdf
    4. Nethercote P, Ermer J. Quality by design for analytical methods: implications for method validation and transfer. Pharm Technol. 2012;36:74–79.
    5. USP 1225: Validation of Compendial Methods. Onine. Last accessed October 25, 2017. http://www.drugfuture.com/Pharmacopoeia/usp32/pub/data/v32270/usp32nf27s0_c1225.html

    Dr. Wayland Rushing is a technical expert in Chemistry Manufacturing and Controls (CMC) program design, analytical development and regulatory submissions. Over his career, he has led CMC development programs for a wide array of pharmaceutical products, including parenterals, inhalation drugs, drug/device combinations and other therapies with complex delivery systems. Dr. Rushing is a subject matter expert in HPLC and GC method development and validation, extractables and leachables program design and regulatory submission requirements; has drafted multiple IND and NDA submissions; and assists EAG clients in responding to FDA deficiency letters.
    Related Searches
    • Validation
    • fda
    • contract manufacturing organization
    • CRO
    Suggested For You
    Pharmaceutical Development for ADCs Pharmaceutical Development for ADCs
    Know the Challenges of Biosimilar Manufacturing Know the Challenges of Biosimilar Manufacturing
    Flexible Manufacturing Strategies and Data Integrity Flexible Manufacturing Strategies and Data Integrity
    Argos Therapeutics Receives $1.5M Milestone Argos Therapeutics Receives $1.5M Milestone
    Analytical Methods for Predicting Protein Stability in Lyophilized Formulations Analytical Methods for Predicting Protein Stability in Lyophilized Formulations
    Sterile Manufacturing: Future Trends and Challenges Sterile Manufacturing: Future Trends and Challenges
    Contracting & Outsourcing Session Highlights and Key Takeaways Contracting & Outsourcing Session Highlights and Key Takeaways
    Ajinomoto Althea Opens GMP Mfg. Suites Ajinomoto Althea Opens GMP Mfg. Suites
    Know the Challenges of  Biosimilar Manufacturing Know the Challenges of Biosimilar Manufacturing
    Catalent Signs Commercial Mfg. Agreement with US WorldMeds Catalent Signs Commercial Mfg. Agreement with US WorldMeds
    Cancer Trials in the New Age of Drug Development Cancer Trials in the New Age of Drug Development
    Senate Passes FDA Reauthorization Act Senate Passes FDA Reauthorization Act
    Warning Letters & Close-out Letters Warning Letters & Close-out Letters
    BioPharma Services Completes 3 FDA Inspections BioPharma Services Completes 3 FDA Inspections
    Frontida BioPharm Launches Expansion Efforts Frontida BioPharm Launches Expansion Efforts

    Related Features

    • Analytical Services | QA/QC
      Newsmakers: LSNE

      Newsmakers: LSNE

      LSNE Expands Capabilities and QC Laboratory Space
      Tim Wright, Editor 05.08.18

    • Analytical Services | Laboratory Testing
      The Time Has Come

      The Time Has Come

      Looking at the change from USP <231> to USP <232> and <233> and what it means.
      Nikki Schopp, Assistant Manager, Analytical Laboratory Services at SGS Life Sciences 04.10.18

    • Analytical Services
      Getting from Risk Assessment to Regulatory Submission

      Getting from Risk Assessment to Regulatory Submission

      Taking the next steps from risk assessment through method development, method validation and testing to the updating of an an
      Anthony DeStefano and Thomas Kester, Recordati Rare Diseases, Inc. 03.09.18


    • Analytical Services | Bioanalytical Services | R&D
      CROs & Next-Gen  Drug Development

      CROs & Next-Gen Drug Development

      R&D trends drive outsourcing in today’s market
      Kristin Brooks, Contract Pharma 05.09.17

    • Analytical Services | Laboratory Testing
      Analytical Testing Outsourcing Trends Update

      Analytical Testing Outsourcing Trends Update

      Spurred by many factors, global analytical testing services market is experiencing rapid growth in the range of 11% per year
      01.26.17

    • Analytical Services | Drug Development | Drug Discovery | Preclinical Outsourcing | R&D
      The Human Parts of Mouse Models

      The Human Parts of Mouse Models

      The PDX model system has come back into focus
      Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company 10.11.16


    • Analytical Services | Bioassay Development | Clinical Trials | Preclinical Outsourcing | R&D
      Robust Assay Designs

      Robust Assay Designs

      Easing the transition from preclinical to clinical research
      Tim Wright, Editor, Contract Pharma 10.11.16

    • Analytical Services | Drug Development | Laboratory Testing
      Elemental Impurity Testing

      Elemental Impurity Testing

      Advances in elemental impurity testing aid compliance with new USP requirements
      Dr. Andrew Fussell, PANalytical 01.28.16

    • Analytical Services | Biosimilars | Clinical Trials | Drug Development | Formulation Development

      Why True CDMO Service Requires Flexibility, Responsiveness and Innovation

      Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
      James E. Gregory, UPM Pharmaceuticals 10.07.15


    • Bioassay Development | Biologics, Proteins, Vaccines | Capsules | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Methods Development | Process Development | QA/QC | Scale-up/Technology Transfer | Toxicology | Validation
      Biopharmaceutical Contract Manufacturing Capacity Expansions

      Biopharmaceutical Contract Manufacturing Capacity Expansions

      Biopharma contract manufacturing market continues to expand, expected to grow 8% over the next five years
      William Downey , HighTech Business Decisions 06.02.15

    • Bioassay Development | Biologics, Proteins, Vaccines | Biosimilars | Clinical Trials | Drug Development | GMPs/GCPs | Inspections | Methods Development | Process Development | Regulatory Affairs | Supply Chain | Toxicology | Validation
      Challenges in Global Biosimilar Development: A Regulatory Perspective

      Challenges in Global Biosimilar Development: A Regulatory Perspective

      More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry.
      Patricia Hurley, Joan Boren and Costantino Congiatu, PPD 06.02.15

    • Bioanalytical Services | Bioassay Development | Biologics, Proteins, Vaccines | Biosimilars | Capsules | Clinical Trials | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Methods Development | Process Development | Process Validation | QA/QC | R&D | Regulatory Affairs | Toxicology | Validation
      A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

      A Case for One Assay Analysis of PK and Immunogenicity in Biosimilar Research

      Moving forward clinical studies will have to include a comparative assessment of pharmacokinetics and immunogenicity to the original reference biologic drug
      Stephanie Mowery, Sherri Rinker, Franklin Spriggs and Bo Kowalcyk , AIT Bioscience 06.02.15

    • Capsules | Cold Chain Management | Drug Development | Extractables and Leachables | Facilities | GMPs/GCPs | Injectables | Inspections | Logistics | Methods Development | Process Development | QA/QC | Regulatory Affairs | Serialization | Solid Dosage/Semi-solids | Supply Chain | Validation | Vials
      Growth Prospects for Pharmaceutical Contract Packaging

      Growth Prospects for Pharmaceutical Contract Packaging

      Spurred by several trends including the patent cliff, new product launches and changes in healthcare, the contract packaging market is looking at sustained growth in the years ahead
      Walt Berghahn , Healthcare Compliance Packaging Council (HCPC) 06.02.15

    • APIs | Bioassay Development | Capsules | Chemistry | Drug Development | Drug Discovery | Excipients | Extractables and Leachables | Facilities | Fill/Finish | Formulation Development | GMPs/GCPs | Lyophilization | Methods Development | Process Development | Process Validation | QA/QC | Solid Dosage/Semi-solids | Supply Chain | Toxicology | Validation
      Continuous Process in Pharmaceutical Manufacturing: Considerations, Nuances and Challenges

      Continuous Process in Pharmaceutical Manufacturing: Considerations, Nuances and Challenges

      A review of the business and process considerations for continuous processing in pharma manufacturing
      Girish Malhotra, EPCOT International 06.02.15

    • Capsules | Clinical Trials | Drug Development | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Inspections | Lyophilization | Methods Development | Process Development | QA/QC | Regulatory Affairs | Risk Management | Validation
      Applying Risk-Based Monitoring in the Real World

      Applying Risk-Based Monitoring in the Real World

      Implementing an acceptable clinical monitoring plan requires a thorough understanding of the new rules under which we’re operating
      Lynn King, TKL Research 06.02.15

    Breaking News
    • Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness
    • Amgen Selects Location For R&D Facility
    • Arctoris Opens Oxford R&D Facility
    • Almac Group, Exostar Collaborate on IRT Experience
    • Northwest Biotherapeutics Expands Management Team
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • Five Ways to Enhance Clinical Operational Efficiencies Utilizing AI
    • Transitioning from Clinical Production to Commercial Manufacturing
    • Clinical Trial Technology
    • Regenerative Medicine: Overcoming the supply chain challenges
    • The Future of the Pharmaceutical Supply Chain
    • Challenges and Opportunities in Vaccines Drug Development
    • Managing Partnerships: Sponsors & CDMOs
    • Towards Sunset or a New Dawn?
    • Biopharma Over 20 Years
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Deerland Obtains Certification from Australia’s Therapeutic Goods Administration
    OptiMSM Shown to Improve Hair & Nail Appearance and Condition
    DCC Acquires Contract Manufacturer Ion Laboratories
    Coatings World

    Latest Breaking News From Coatings World

    Arkema: Bostik Acquires Danish Company LIP
    Axalta Adds New Epoxy Primer to Tufcote Liquid Industrial Coatings Portfolio
    Chromaflo Technologies Promotes Sergio Duenas to Country Manager of Mexico
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs World's First Single-Use Duodenoscope
    Dr. Stephen Hahn Confirmed as New FDA Leader
    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sanofi Awarded $226M by US Gov't for Pandemic Influenza Preparedness
    Amgen Selects Location For R&D Facility
    Arctoris Opens Oxford R&D Facility
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Time Features 5 Best Beauty Inventions
    CES 2020 Preview - Innovation Award Honorees in Health & Wellness
    Prada & L’Oréal Sign Long-Term Licensing Deal
    Happi

    Latest Breaking News From Happi

    Cosmetic Assessments Revealed at CIR Panel
    T-Boz Launches CBD Line
    DRF and Flowerkist Develop CBD Range
    Ink World

    Latest Breaking News From Ink World

    Ripon Printers Adds Ricoh Pro C9210
    LogoJet Opens Bogota, Colombia Office
    Canon Solutions America Powers University of Notre Dame Athletics' Printing Capabilities
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    GSE products provide quality assurance for Pharmalabel
    Luminer promotes Heather Bookman to prepress manager
    Materials Exchange launches to solve excess inventory issue
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    DuPont to Acquire Osmosis Specialist
    Nice-Pak to Expand in Indiana
    Hospeco Launches Compact Fem Hy Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    FDA OKs First Test to Help Screen for Newborn Duchenne Muscular Dystrophy
    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    TriMed Closes Out FDA Warning Letter
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    3D Printing Materials Market to Grow at 23.9% CAGR Through 2025: GVR
    Kyocera, TactoTek Collaborate on Injection Molded Structural Electronics Solutions
    Toray Opens R&D Innovation Center for the Future

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.